

F-VASI50 Response
F-VASI50 Response, %
Vehicle (n=32)
0.15% QD (n=31)
0.5% QD (n=31)
1.5% QD (n=30)
1.5% BID (n=33)
Week 4
Week 8
Week 12
Week 18
Week 24
Error bars indicate standard error
*** P<0.001 vs vehicle at Week 24; ** P<0.01 vs vehicle at Week 24; * P<0.05 vs vehicle at Week 24.

FIG. 1




F-VASI75 Response
F-VASI75 Response, %
0
10
20
30
40
Vehicle (n=32)
0.15% QD (n=31)
0.5% QD (n=31)
1.5% QD (n=30)
1.5% BID (n=33)
Week 4
Week 8
Week 12
Week 18
Week 24
0
3.2
3.3
0
3.2
3.2
6.7
6.1
0
6.5
9.7
16.7
9.1
0
12.9
16.1
16.7
24.2
0
9.7
16.1
16.7
30.3
Error bars indicate standard error.

FIG. 2

F-PhGVA of Clear or Almost Clear at Week 24





Percentage Change From Baseline in F-VASI
Mean (SEM) Percentage Change From Baseline in F-VASI
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
Vehicle (n=32)
0.15% QD (n=31)
0.5% QD (n=31)
1.5% QD (n=30)
1.5% BID (n=33)
0.15% QD
vehicle
0.5% QD
1.5% BID
1.5% QD
Baseline
Week 4
Week 8
Week 12
Week 18
Week 24

FIG. 4



Proportion of Subjects Achieving F-VASI50 Response by Visit and Treatment Group up to Week 52
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Proportion of F-VASI50 Response (%)
Treatment Group:
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Number of Subjects at Visit
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52

FIG. 5



Proportion of Subjects Achieving F-VASI50 Response by Visit and Treatment Group up to Week 52 (LOCF)
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Proportion of F-VASI50 Response (%)
0
10
20
30
40
50
60
70
80
Treatment Group:
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit

FIG. 6



Proportion of Subjects Achieving F-VASI25 Response by Visit and Treatment Group up to Week 52
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Proportion of F-VASI25 Response (%)
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Number of Subjects at Visit
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52

FIG. 7



Proportion of Subjects Achieving F-VASI25 Response by Visit and Treatment Group up to Week 52 (LOCF)
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Proportion of F-VASI25 Response (%)
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Number of Subjects at Visit
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52

FIG. 8




Proportion of Subjects Achieving F-VASI75 Response by Visit and Treatment Group up to Week 52
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Proportion of F-VASI75 Response (%)
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Number of Subjects at Visit
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52

FIG. 9



Proportion of Subjects Achieving F-VASI75 Response by Visit and Treatment Group up to Week 52 (LOCF)
(Population: Intent-to-Treat Subjects: Double-Blind Period)

FIG. 10




FIG. 11

Proportion of Subjects Achieving F-VASI90 Response by Visit and Treatment Group up to Week 52
(Population: Intent-to-Treat Subjects: Double-Blind Period)




Proportion of Subjects Achieving F-VASI90 Response by Visit and Treatment Group up to Week 52 (LOCF)
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Proportion of F-VASI90 Response (%)
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Number of Subjects at Visit
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52

FIG. 12

FIG. 13


Mean and Standard Error of Change from Baseline in F-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Mean Change from Baseline in F-VASI Score
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Vehicle BID
0.15% QD
0.5% QD
1.5% BID
1.5% QD
BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit



Mean Percentage Change from Baseline in F-VASI Score
Mean and Standard Error of Percentage Change from Baseline in F-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Vehicle BID
0.15% QD
1.5% BID
1.5% QD
0.5% QD
Number of Subjects at Visit
BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52

FIG. 14




FIG. 15

Mean and Standard Error of Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)





FIG. 16

Mean and Standard Error of Percentage Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)



Proportion of Subjects Achieving T-VASI50 Response by Visit and Treatment Group up to Week 52
(Population: Intent-to-Treat Subjects: Double-Blind Period)

FIG. 17




FIG. 18

Proportion of Subjects Achieving T-VASI50 Response by Visit and Treatment Group up to Week 52 (LOCF)
(Population: Intent-to-Treat Subjects: Double-Blind Period)




FIG. 19

Proportion of Subjects Achieving T-VASI25 Response by Visit and Treatment Group up to Week 52
(Population: Intent-to-Treat Subjects: Double-Blind Period)

FIG. 20



Proportion of Subjects Achieving T-VAS125 Response by Visit and Treatment Group up to Week 52 (LOCF)
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Treatment Group:
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VAS125 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID

FIG. 21



Mean and Standard Error of Change from Baseline in T-BSA by Visit and Treatment Group
(Population: Intent-to-Treat Subjects; Double-Blind Period)
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Mean Change from Baseline in T-BSA
Vehicle BID
0.15% QD
0.5% QD
1.5% QD
1.5% BID
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 18 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit

FIG. 22



Mean and Standard Error of Percentage Change from Baseline in T-BSA by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)
Treatment Group
Vehicle BID
INCB018424 0.15% QD
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Mean Percentage Change from Baseline in T-BSA
Vehicle BID
0.15% QD
0.5% QD
1.5% BID
1.5% QD
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 18 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit

FIG. 23



Proportion of Subjects Achieving T-VASI25 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Head and Neck Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI25 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/19 1/19 3/19 3/19 3/19
Combined Group 9/59 13/59 18/59 24/59 29/59 38/59 31/59 36/59 37/59 38/59
INCB018424 0.5% QD 4/20 4/20 5/20 6/20 7/20 8/20 9/20 13/20 14/20 15/20
INCB018424 1.5% QD 2/19 4/19 5/19 5/19 11/19 9/19 13/19 8/19 8/19 8/19
INCB018424 1.5% BID 3/20 5/20 8/20 9/20 11/20 11/20 13/20 15/20 15/20 15/20
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 24



Proportion of Subjects Achieving T-VAS150 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Head and Neck Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VAS150 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/19 1/19 1/19 1/19 1/19
Combined Group 7/59 9/59 15/59 18/59 23/59 24/59 23/59 24/59 27/59 28/59
INCB018424 0.5% QD 3/20 3/20 5/20 6/20 6/20 7/20 7/20 8/20 9/20 10/20
INCB018424 1.5% QD 1/19 3/19 3/19 5/19 8/19 6/19 6/19 4/19 6/19 6/19
INCB018424 1.5% BID 3/20 3/20 7/20 7/20 9/20 11/20 10/20 12/20 12/20 12/20
Abbreviation: T-VAS = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved response.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 25



Proportion of Subjects Achieving T-VAS175 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Head and Neck Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% BID
Proportion of T-VAS175 Response (%)
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 8/19 8/19 8/19 6/19 6/19
Combined Group 4/59 4/59 7/59 13/59 16/59 18/59 18/59 19/59 22/59 23/59
INCB018424 0.5% QD 1/20 1/20 2/20 5/20 6/20 7/20 6/20 5/20 7/20 6/20
INCB018424 1.5% QD 1/19 1/19 1/19 2/19 3/19 3/19 4/19 4/19 5/19 5/19
INCB018424 1.5% BID 2/20 2/20 4/20 6/20 7/20 8/20 8/20 10/20 10/20 11/20
Abbreviation: T-VAS = Total body assessment of the lesion area and severity index
Note: Missing post-baseline values are considered as not having achieved response.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD

FIG. 26




Mean and Standard Error of Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Head and Neck only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Mean Change from Baseline in T-VASI Score
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
-1.6
-1.8
-2.0
Vehicle BID
Combined Group
1.5% BID
1.5% QD
0.5% QD
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 18 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 19 18 18 17 17 16
Combined Group 59 57 55 55 55 55 53 54 50 49 49
INCB018424 0.5% QD 20 20 20 19 20 20 19 20 19 19 19
INCB018424 1.5% QD 19 18 18 17 16 16 15 15 12 12 12
INCB018424 1.5% BID 20 19 19 19 19 19 19 19 19 18 18
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 27



	BASELINE	WEEK 4	WEEK 8	WEEK 12	WEEK 18	WEEK 24	WEEK 28	WEEK 34	WEEK 40	WEEK 46	WEEK 52
Number of Subjects at Visit											
Vehicle BID	18	18	18	17	17	16					
Combined Group	59	57	55	55	55	55	53	54	50	49	49
INCB018424 0.5% QD	20	20	20	19	20	20	19	20	19	19	19
INCB018424 1.5% QD	19	18	16	17	16	16	15	15	12	12	12
INCB018424 1.5% BID	**20**	**19**	**19**	**19**	**19**	**19**	**19**	**19**	**19**	**18**	**18**

Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 28




Proportion of Subjects Achieving T-VAS125 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Hands Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VAS125 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/17 0/17 1/17 1/17 1/17 1/17 1/17 1/17 1/17 1/17
Combined Group 7/58 7/58 14/58 16/58 19/58 19/58 21/58 22/58 22/58 22/58
INCB018424 0.5% QD 6/19 5/19 6/19 8/19 7/19 7/19 8/19 8/19 8/19 10/19
INCB018424 1.5% QD 1/19 2/19 6/19 5/19 6/19 8/19 8/19 6/19 6/19 5/19
INCB018424 1.5% BID 0/20 0/20 1/20 3/20 4/20 4/20 5/20 8/20 8/20 7/20
Abbreviation: T-VAS = Total body assessment of the Vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD

FIG. 29



Abbreviation: T-VAS = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group: includes 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 30



Proportion of Subjects Achieving T-VASI75 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Hands Only
Treatment Group
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI75 Response (%)
0
5
10
15
20
25
30
35
40
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/17 0/17 0/17 0/17 0/17 0/17 0/17 0/17 0/17 0/17
Combined Group 2/58 3/56 5/58 4/58 4/58 5/58 8/58 8/58 8/58 9/58
INCB018424 0.5% QD 2/19 2/19 2/19 2/19 2/19 3/19 3/19 3/19 3/19 4/19
INCB018424 1.5% QD 0/19 1/19 3/19 1/19 2/19 1/19 4/19 4/19 4/19 4/19
INCB018424 1.5% BID 0/20 0/20 1/20 1/20 1/20 1/20 1/20 1/20 1/20 1/20
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 31



Mean and Standard Error of Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Hands only
Treatment Group
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Mean Change from Baseline in T-VASI Score
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
-0.7
-0.8
-0.9
-1.0
Vehicle BID
Combined Group
1.5% QD
0.5% QD
1.5% BID
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 16 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 17 17 17 16 16 15
Combined Group 38 36 34 35 34 34 33 33 32 49 49
INCB018424 0.5% QD 19 19 19 19 19 19 19 19 19 19 19
INCB018424 1.5% QD 19 19 18 17 18 16 15 15 12 12 12
INCB018424 1.5% BID 20 19 19 19 19 19 19 19 19 18 18
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD

FIG. 32



Mean and Standard Error of Percentage Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Hands only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Vehicle BID
1.5% BID
Combined Group
0.5% QD
1.5% QD
Mean Percentage Change from Baseline in T-VASI Score
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 16 WEEK 20 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 17 17 17 16 16 15
Combined Group 58 56 54 55 54 54 52 53 50 49 49
INCB018424 0.5% QD 19 19 19 19 19 19 18 19 19 19 19
INCB018424 1.5% QD 18 18 16 17 16 16 15 15 12 12 12
INCB018424 1.5% BID 20 19 19 19 19 19 19 19 19 18 18
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 33



Proportion of Subjects Achieving T-VASI25 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Upper Extremities Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI25 Response (%)
0
10
20
30
40
50
60
70
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/18 0/18 2/18 3/18 1/18
Combined Group 3/52 10/52 13/52 18/52 20/52 19/52 23/52 28/52 27/52 27/52
INCB018424 0.5% QD 2/17 3/17 5/17 6/17 5/17 5/17 7/17 9/17 8/17 8/17
INCB018424 1.5% QD 2/18 5/18 6/18 8/18 8/18 8/18 8/18 8/18 8/18 8/18
INCB018424 1.5% BID 1/17 2/17 2/17 4/17 6/17 6/17 8/17 10/17 10/17 10/17
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group includes 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 34



Proportion of Subjects Achieving T-VAS150 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Upper Extremities Only
Treatment Group
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VAS150 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/18 0/18 1/18 0/18 1/18
Combined Group 3/52 7/52 10/52 14/52 13/52 15/52 16/52 21/52 21/52 23/52
INCB018424 0.5% QD 1/17 2/17 3/17 3/17 3/17 4/17 4/17 6/17 6/17 7/17
INCB018424 1.5% QD 0/18 4/18 6/18 8/18 7/18 7/18 7/18 8/18 8/18 7/18
INCB018424 1.5% BID 1/17 1/17 1/17 3/17 3/17 4/17 5/17 7/17 7/17 9/17
Abbreviation: T-VAS = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved response.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 35



Proportion of Subjects Achieving T-VAS175 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Upper Extremities Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VAS175 Response (%)
0
5
10
15
20
25
30
35
40
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/18 0/18 0/18 0/18 0/18 0/18 0/18 0/18 0/18 0/18
Combined Group 1/52 0/53 6/52 6/53 10/52 9/53 10/52 11/53 11/52 11/53
INCB018424 0.5% QD 0/17 0/17 1/17 2/17 3/17 3/17 3/17 3/17 4/17 4/17
INCB018424 1.5% QD 0/18 0/18 4/18 3/18 5/18 3/18 5/18 4/18 3/18 3/18
INCB018424 1.5% BID 1/17 0/17 1/17 1/17 2/17 3/17 2/17 4/17 4/17 4/17
Abbreviations: T-VAS = Total body assessment of the eczema area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 36




Mean and Standard Error of Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Upper Extremities only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Mean Change from Baseline in T-VASI Score
Combined Group
Vehicle BID
0.5% QD
1.5% QD
1.5% BID
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 18 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 18 18 18 17 17 16 16 16 15 15 15
Combined Group 52 51 49 50 49 49 47 48 45 45 45
INCB018424 0.5% QD 17 17 17 17 17 17 16 17 17 17 17
INCB018424 1.5% QD 18 18 18 17 18 16 15 15 13 13 12
INCB018424 1.5% BID 17 16 16 16 16 16 15 16 16 16 16
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 37



Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group includes 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 38



Proportion of Subjects Achieving T-VASI25 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Trunk Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI25 Response (%)
0
10
20
30
40
50
60
70
80
0.0
11.8
25.0
0.0
11.1
15.7
19.1
25.0
22.2
0.0
18.7
25.0
18.8
37.5
12.5
18.7
28.4
12.5
55.6
17.6
11.1
31.4
25.0
50.0
17.6
34.2
11.8
35.0
34.2
49.0
41.2
61.4
47.1
43.1
31.3
54.9
54.6
42.1
47.4
52.6
50.0
52.9
Number of Subjects at Visit
Vehicle BID 0/18 2/18 3/18 3/18 2/18 2/51 5/18 22/51 22/51 24/51
Combined Group 6/51 8/51 13/51 15/51 16/51 21/51 25/51 22/51 22/51 24/51
INCB018424 0.5% QD 4/16 4/16 3/16 2/16 4/16 5/16 6/16 5/16 6/16 6/16
INCB018424 1.5% QD 2/18 4/18 7/19 10/18 5/18 9/18 11/18 8/18 8/18 9/18
INCB018424 1.5% BID 0/17 0/17 3/17 3/17 3/17 7/17 8/17 9/17 9/17 9/17
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 39




Proportion of Subjects Achieving T-VAS150 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Trunk Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% BID
Proportion of T-VAS150 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 20
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/18 0/18 1/18 0/18 0/18 0/18 1/18 1/18 1/18 1/18 1/18
Combined Group 0/51 3/51 7/51 10/51 11/51 13/51 17/51 14/51 14/51 16/51
INCB018424 0.5% QD 0/16 1/16 1/16 1/16 1/16 2/16 5/16 5/16 5/16 4/16
INCB018424 1.5% QD 0/18 2/18 5/18 6/18 7/18 7/18 6/18 6/18 7/18 7/18
INCB018424 1.5% BID 0/17 0/17 1/17 1/17 3/17 4/17 4/17 3/17 2/17 5/17
Abbreviation: T-VAS = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 40



Abbreviation: T-VASI = Total tech assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved response.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 41



Mean and Standard Error of Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Trunk only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Vehicle BID
1.5% BID
1.5% QD
0.5% QD
Combined Group
Mean Change from Baseline in T-VASI Score
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
-1.6
-1.8
-2.0
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 18 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 18 18 18 17 17 16 16 16 16 16
Combined Group 51 49 48 48 48 48 47 47 43 42 42
INCB018424 0.5% QD 16 16 16 15 16 16 16 16 15 15 15
INCB018424 1.5% QD 18 17 16 17 16 16 15 15 12 12 12
INCB018424 1.5% BID 17 16 16 16 16 16 16 16 16 15 15
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 42



Mean and Standard Error of Percentage Change from Baseline in T-VAS) Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Trunk only
Treatment Group
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Vehicle BID
Combined Group
1.5% BID
1.5% QD
0.5% QD
Mean Percentage Change from Baseline in T-VAS) Score
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 16 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 16 18 16 17 17 16 47 43 42 42
Combined Group 51 49 48 48 48 48 47 47 42 42
INCB018424 0.5% QD 16 16 16 15 16 16 16 15 15 15
INCB018424 1.5% QD 18 17 16 17 16 16 16 12 12 13
INCB018424 1.5% BID 17 16 16 16 16 16 16 16 15 15
Abbreviation: T-VAS) = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD

FIG. 43




Proportion of Subjects Achieving T-VASI50 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Lower Extremities Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI50 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/16 0/16 0/16 0/16 0/16
Combined Group 1/50 5/50 10/50 11/50 14/50 14/50 14/50 15/50 17/50 20/50
INCB018424 0.5% QD 1/13 1/13 2/13 2/13 2/13 2/13 2/13 2/13 2/13 4/13
INCB018424 1.5% QD 0/16 2/16 4/16 6/16 4/16 4/16 4/16 5/16 6/16 6/16
INCB018424 1.5% BID 0/19 2/19 4/19 3/19 6/19 8/19 8/19 8/19 9/19 10/19
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved response.
Combined group included 1.5%BID, 1.5%QD and 0.5%QD.

FIG. 44



Number of Subjects at Visit	WEEK 4	WEEK 8	WEEK 12	WEEK 18	WEEK 24	WEEK 28	WEEK 34	WEEK 40	WEEK 46	WEEK 52
Vehicle BID	0/16	0/16	0/16	0/16	1/16					
Combined Group	4/50	9/50	16/50	18/50	21/50	21/50	23/50	23/50	22/50	25/50
INCB018424 0.5% QD	1/13	2/13	5/13	4/13	3/13	3/13	3/13	3/13	3/13	5/13
INCB018424 1.5% QD	3/16	5/16	7/16	8/16	8/16	7/16	8/16	7/16	7/16	7/16
INCB018424 1.5% BID	0/19	2/19	4/19	6/19	10/19	11/19	12/19	13/19	12/19	13/19

Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 45



Proportion of Subjects Achieving T-VAS175 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Lower Extremities Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VAS175 Response (%)
0
5
10
15
20
25
30
35
40
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 20
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/16 0/16 0/16 0/16 0/16 0/16 0/16 0/16 0/16 0/16 0/16
Combined Group 0/50 0/50 4/50 6/50 7/50 8/50 8/50 8/50 10/50 11/50
INCB018424 0.5% QD 0/13 0/13 1/13 0/13 1/13 2/13 2/13 1/13 2/13 2/13
INCB018424 1.5% QD 0/18 0/18 1/18 4/18 3/18 2/18 2/18 3/18 3/18 3/18
INCB018424 1.5% BID 0/19 0/19 2/19 2/19 3/19 4/19 4/19 4/19 5/19 5/19
Abbreviation: T-VAS = Total body assessment of the vitiligo area and severity index.
Note: Missing postbaseline values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 46



Mean and Standard Error of Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Lower Extremities only
Treatment Group
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Mean Change from Baseline in T-VASI Score
0.8
0.6
0.4
0.2
0.0
-0.2
-0.4
-0.6
-0.8
-1.0
-1.2
-1.4
-1.6
-1.8
-2.0
Vehicle BID
0.5% QD
Combined Group
1.5% QD
1.5% BID
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 16 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 16 16 16 16 16 15 15 42 42 42
Combined Group 50 48 46 47 46 46 44 45 42 42 42
INCB018424 0.5% QD 13 13 13 13 13 13 12 13 13 13 13
INCB018424 1.5% QD 18 17 15 16 15 15 14 14 11 11 11
INCB018424 1.5% BID 19 18 18 18 18 18 18 18 18 18 18
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD

FIG. 47



Mean and Standard Error of Percentage Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects: Double-Blind Period)-Lower Extremities only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Vehicle BID
Combined Group
0.5% QD
1.5% QD
1.5% BID
Mean Percentage Change from Baseline in T-VASI Score
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 16 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 16 16 16 16 16 15 15 15 15 15 15
Combined Group 50 46 46 47 46 46 44 45 42 42 42
INCB018424 0.5% QD 13 13 13 13 13 13 12 13 13 13 13
INCB018424 1.5% QD 18 17 16 16 15 15 14 14 11 11 11
INCB018424 1.5% BID 19 18 18 18 18 18 18 18 18 18 18
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 48



Proportion of Subjects Achieving T-VASI50 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Feet Only
Treatment Group
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI50 Response (%)
0
10
20
30
40
50
60
70
80
WEEK 4
WEEK 8
WEEK 12
WEEK 16
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/14 0/14 1/14 0/14 0/14
Combined Group 4/50 8/50 8/50 11/50 11/50 8/50 8/50 8/50 10/50 12/50
INCB018424 0.5% QD 2/14 2/14 2/14 1/14 1/14 1/14 1/14 1/14 3/14 2/14
INCB018424 1.5% QD 1/19 3/19 4/19 6/19 6/19 5/19 5/19 4/19 5/19 5/19
INCB018424 1.5% BID 1/17 3/17 3/17 4/17 4/17 2/17 2/17 3/17 3/17 5/17
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 49



Proportion of Subjects Achieving T-VASI25 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Feet Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI25 Response (%)
0
10
20
30
40
50
60
70
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 8/14 8/14 2/14 2/14 8/14
Combined Group 8/50 9/50 9/50 13/50 14/50 17/50 16/50 16/50 16/50 16/50
INCB018424 0.5% QD 3/14 2/14 2/14 2/14 2/14 4/14 4/14 4/14 4/14 4/14
INCB018424 1.5% QD 3/19 3/19 4/19 4/19 6/19 6/19 7/19 5/19 5/19 5/19
INCB018424 1.5% BID 2/17 4/17 3/17 5/17 6/17 7/17 5/17 7/17 7/17 7/17
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing data/Indeterminate values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 50



Proportion of Subjects Achieving T-VASI75 Response by Visit and Treatment Group up to Week 52
Population: Intent-to-Treat Subjects: Double-Blind Period-Feet Only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Proportion of T-VASI75 Response (%)
0
5
10
15
20
25
30
35
40
WEEK 4
WEEK 8
WEEK 12
WEEK 18
WEEK 24
WEEK 28
WEEK 34
WEEK 40
WEEK 46
WEEK 52
Number of Subjects at Visit
Vehicle BID 0/14 0/14 0/14 0/14 0/14 0/14 0/14 0/14 0/14 0/14
Combined Group 2/58 3/58 6/58 9/58 8/58 6/58 7/58 5/58 6/58 8/58
INCB018424 0.5% QD 1/14 1/14 1/14 1/14 0/14 0/14 0/14 0/14 1/14 1/14
INCB018424 1.5% QD 1/19 1/19 3/19 4/19 3/19 4/19 3/19 4/19 4/19 4/19
INCB018424 1.5% BID 0/17 1/17 2/17 4/17 3/17 2/17 2/17 1/17 1/17 3/17
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Note: Missing post-baseline values are considered as not having achieved responses.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD.

FIG. 51




Mean and Standard Error of Change from Baseline in T-VASI Score by Visit and Treatment Group
(Population: Intent-to-Treat Subjects; Double-Blind Period)-Feet only
Treatment Group:
Vehicle BID
Combined Group
INCB018424 0.5% QD
INCB018424 1.5% QD
INCB018424 1.5% BID
Vehicle BID
0.5% QD
Combined Group
1.5% QD
1.5% BID
Mean Change from Baseline in T-VASI Score
0.5
0.3
0.1
-0.1
-0.3
-0.5
-0.7
-0.9
BASELINE WEEK 4 WEEK 8 WEEK 12 WEEK 18 WEEK 24 WEEK 28 WEEK 34 WEEK 40 WEEK 46 WEEK 52
Number of Subjects at Visit
Vehicle BID 13 14 14 13 13 12
Combined Group 50 48 46 47 46 46 44 45 42 42 42
INCB018424 0.5% QD 14 14 14 14 14 14 13 14 14 14 14
INCB018424 1.5% QD 19 16 16 17 16 16 13 13 13 13 13
INCB018424 1.5% BID 17 16 16 16 16 16 16 16 16 16 16
Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5%BID, 1.5%QD, and 0.5%QD

FIG. 52



Number of Subjects at Visit	BASELINE	WEEK 4	WEEK 8	WEEK 12	WEEK 18	WEEK 24	WEEK 28	WEEK 34	WEEK 40	WEEK 46	WEEK 52
Vehicle BID	14	14	14	13	13	12					
Combined Group	50	48	46	47	46	46	44	45	42	42	42
INCB018424 0.5% QD	14	13	14	14	14	14	13	14	14	14	14
INCB018424 1.5% QD	19	18	18	17	16	16	15	15	12	12	12
INCB018424 1.5% BID	17	16	16	16	16	16	16	16	16	16	16

Abbreviation: T-VASI = Total body assessment of the vitiligo area and severity index.
Combined group included 1.5% BID, 1.5% QD, and 0.5% QD.

FIG. 53

P-Values from Fisher Exact Test between Combined Group and Vehicle Group at Week 24:

	Head	Hands	Upper	Trunk	Lower	Feet
T-VAS#3	0.0147	0.0307	0.0079	0.1236	0.0127	0.0279
T-VAS#6	0.0046	0.4382	0.0957	0.0549	0.0151	0.1027
T-VAS#5	0.0085	0.5684	0.0545	0.3162	0.1815	0.1831

FIG. 54



T-VAS150 Response, %†
60
50
40
30
20
10
0
Vehicle (n=19)
0.15% QD (n=22)
0.5% QD (n=20)
1.5% QD (n=19)
1.5% BID (n=20)
0
9.1
10.0
5.3
0
5.3
18.2
18.0
10.5
10.0
0
18.2
31.6
20.0
10.0
20.0
42.1
25.0
20.0
25.0
36.8
46.0
Week 8
Week 12
Week 24
Week 34
Week 52
Double-Blind Vehicle-Controlled
Double-Blind

FIG. 55



A
Mean (SEM) Percentage Change From Baseline in F-BSA
Vehicle
0.5% QD
1.5% QD
1.5% BID
0.15% QD

FIG. 56



A
Missing
Severe disease
Moderate disease
Mild disease
Almost clear
Clear
F-PhGVA by Disease Category, %
100
80
60
40
20
0
n
32
31
31
30
33
32
31
31
30
33
29
21
29
Veh
0.15% QD
0.5% QD
1.5% QD
1.5% BID
Baseline
Week 24
Week 52
B
T-PhGVA by Disease Category, %*
100
80
60
40
20
0
n
19
22
20
19
20
16
19
20
16
19
19
12
18
Veh
0.15% QD
0.5% QD
1.5% QD
1.5% BID
Baseline
Week 24
Week 52

FIG. 57



A
F-PaGVA by Disease Category, %
Missing
Very Severe
Severe
Moderate
Mild
No White Patches
Veh
0.15% QD
0.5% QD
1.5% QD
1.5% BID
Baseline
Week 24
Week 52
B
T-PaGVA by Disease Category, %*
Week 62

FIG. 58




FIG. 59

	WEEK 24		WEEK 52		
	VEHICLE	RUXOLITINIB CREAM			
PARAMETER, N (%)	BID (N=32)	0.15% QD (N=31)	0.5% QD (N=31)	1.5% QD (N=30)	1.5% BID (N=33)
PATIENTS WITH TEAE	20 (62.5)	20 (64.5)	26 (83.9)	23 (76.7)	23 (69.7)
MOST COMMON TEAES*					
ACNE	1 (3.1)	4 (12.9)	5 (16.1)	3 (10.0)	6 (18.2)
VIRAL UPPER RESPIRATORY TRACT INFECTION	5 (15.6)	3 (9.7)	3 (9.7)	6 (20.0)	1 (3.0)
APPLICATION SITE PRURITUS	3 (9.4)	6 (19.4)	3 (9.7)	3 (10.0)	1 (3.0)
PRURITUS	3 (9.4)	1 (3.2)	5 (16.1)	4 (13.3)	3 (9.1)
UPPER RESPIRATORY TRACT INFECTION	0	1 (3.2)	5 (16.1)	1 (3.3)	3 (9.1)
HEADACHE	3 (9.4)	1 (3.2)	0	3 (10.0)	2 (6.1)
SINUSITIS	1 (3.1)	2 (6.5)	1 (3.2)	2 (6.7)	2 (6.1)
PATIENTS WITH TREATMENT-RELATED TEAE	12 (37.5)	11 (35.5)	12 (38.7)	12 (40.0)	10 (30.3)
MOST COMMON TREATMENT-RELATED TEAES*					
APPLICATION SITE PRURITUS	3 (9.4)	6 (19.4)	3 (9.7)	3 (10.0)	1 (3.0)
ACNE	1 (3.1)	1 (3.2)	3 (9.7)	3 (10.0)	6 (18.2)
PRURITUS	2 (6.3)	1 (3.2)	4 (12.9)	3 (10.0)	2 (6.1)
PATIENTS WITH TEAE LEADING TO DISCONTINUATION†	1 (3.1)	1 (3.2)‡	0	1 (3.3)	0
PATIENTS WITH SERIOUS TEAE§	0	0	2 (6.5)	1 (3.3)	1 (3.0)

BID, TWICE DAILY; QD, ONCE DAILY; TEAE, TREATMENT-EMERGENT ADVERSE EVENT.


* OCCURRING IN >5% OF THE TOTAL PATIENT POPULATION.

† TEAES LEADING TO DISCONTINUATION WERE NOT RELATED TO TREATMENT UNLESS OTHERWISE INDICATED.

‡ HEADACHE RELATED TO TREATMENT.

§ NO SERIOUS TEAES WERE RELATED TO TREATMENT

FIG. 60



Number of Patients at Visit											
Vehicle	32	29	28	28	25	27					
0.15% QD	31	27	26	27	25	26					
0.5% QD	31	31	31	29	30	30	29	29	28	27	
1.5% QD	30	29	25	26	26	26	24	25	21	20	
1.5% BID	33	31	31	30	30	30	29	30	29	28	

FIG. 61





ULN
LLN
Vehicle (n=32)
0.15% QD (n=31)
0.5% QD (n=31)
1.5% QD (n=30)
1.5% BID (n=33)
0.15% QD
Vehicle
1.5% QD
1.5% BID
0.5% QD
Mean (SEM) Platelets, 10⁹/L
450
425
400
375
350
325
300
275
250
225
200
175
150
0
Baseline
Week 4
Week 8
Week 12
Week 18
Week 24
Week 28
Week 34
Week 40
Week 46
Week 52
Number of Patients at Visit
Vehicle 32 29 28 28 25 27
0.15% QD 31 27 25 27 25 26
0.5% QD 31 31 30 29 30 30 29 28 28 28 27
1.5% QD 30 29 25 26 26 26 24 25 21 21 20
1.5% BID 33 31 31 30 30 30 29 30 30 29 28

FIG. 62




F-VASI50, 50% improvement in facial Vitiligo Area Scoring Index; SE, standard error

FIG. 63



BID, twice daily; F-BSA, facial body surface area; F-VASI50, 50% improvement in facial Vitiligo Area Scoring Index; SE, standard error; T-BSA, total body surface area.

FIG. 64



F-VASI50, 50% improvement in facial Vitiligo Area Scoring Index; SE, standard error; TCI, topical calcineurininhibitors; TCS, topical corticosteroids.

* Determination of disease stability was based on investigator judgment.

†Patients could have used ≥1 previous therapy.